SR9009

Metabolic / Fat Loss

Also known as: Stenabolic, SR-9009

Rev-Erb AgonistsResearch phase: PreclinicalRegulatory: Not FDA-approved. Research chemical only. No human clinical trials. WADA prohibited substance.

Mechanism

SR9009 (Stenabolic) is a Rev-Erb-alpha agonist that influences circadian rhythm genes controlling metabolism, fat storage, and energy expenditure. In animal studies, it increased exercise capacity, reduced fat mass, and improved mitochondrial function. It has very poor oral bioavailability (approximately 2%), which significantly limits its practical effectiveness when taken orally despite widespread marketing as an oral compound.

Technical detail

SR9009 is a synthetic agonist of Rev-Erbα (NR1D1), a nuclear receptor that functions as a transcriptional repressor within the circadian clock machinery. Activation of Rev-Erbα by SR9009 modulates the expression of genes involved in lipogenesis (SREBP1c, FAS), fatty acid oxidation (CPT1, UCP3), mitochondrial biogenesis (PGC-1α), and autophagy (ATG genes). In murine models, it reduced body fat, increased running endurance by ~50%, and improved mitochondrial content in skeletal muscle. However, pharmacokinetic studies reveal oral bioavailability of approximately 2% in mice, raising serious questions about efficacy of oral dosing in humans.